Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinic... Tekijä Mohammad Ali Sahraian, Roya Abolfazli, Vahid Shaygannejad, Fereshteh Ashtari, Nastaran Majdinasab, Samira Navardi, Seyed Mohammad Baghbanian, Behnaz Sedighi, Abdorreza Naser Moghadasi, Mohammad Ali Nahayati, Hamidreza Ghalyanchi Langroodi, Seyed Ehsan Mohammadianinejad, Nahid Beladi Moghadam, Hormoz Ayromlou, Alireza Nikseresht, Masoud Ghiasian, Nazanin Razazian, Elnaz Asadollahzadeh, Araz Sabzvari, Hamidreza Kafi, Sogol Albooyeh

Hae kokoteksti